Interferon-alpha in the management of patients with Behçet's disease

British Journal of Hospital Medicine

Volumn 69, Issue 10, 2008, Pages 575-579

  Yang, David S F ^a   Taylor, Simon R J ^a   Lightman, Sue L ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 54849435306     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2008.69.10.31317     Document Type: Review

References (31)

1. Abbas AK (2003) The control of T cell activation vs. tolerance. Autoimmun Rev 2(3): 115-18
2. Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, Basaran E (2002) Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 138(4): 467-71
3. Amberger M, Groll S, Gunaydin I, Deuter C, Vonthein R, Kotter I (2007) Intracellular cytokine patterns in Behcet's disease in comparison to ankylosing spondylitis - influence of treatment with interferon-alpha2a. Clin Exp Rheumatol 25(4 Suppl 45): S52-S57
4. Antonelli G, Currenti M, Turriziani O et al (1991) Neutralizing antibodies to interferon-alpha - relative frequency in patients treated with different interferon preparations. J Infect Dis 163: 882-5
5. Azizlerli G, Sarica R, Kose A et al (1997) The long-term treatment with interferon alpha-2a in Behcet's disease. In: Hamza M, ed. Behcet's Disease. Adhoua, Tunis: 453-5
6. Baccala R, Kono DH, Theofilopoulos AN (2005) Interferons as pathogenic effectors in autoimmunity. Immunol Rev 204: 9-26
7. Bodaghi B, Gendron G, Wechsler B et al (2007) Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 91(3): 335-9
8. Brinkmann V, Geiger T, Alkan S, Heusser CH (1993) Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Med 178(5): 1655-63
9. Calguneri M, Ozturk MA, Ertenli I, Kiraz S, Apras S, Ozbalkan Z (2003) Effects of interferon alpha treatment on the clinical course of refractory Behcet's disease: an open study. Ann Rheum Dis 62(5): 492-3
10. Deuter CM, Kotter I, Wallace GR, Murray PI, Stubiger N, Zierhut M (2008) Behcet's disease: ocular effects and treatment. Prog Retin Eye Res 27(1): 111-36
11. Eguchi K, Kawakami A, Nakashima M et al (1992) Interferon-alpha and dexamethasone inhibit adhesion of T cells to endothelial cells and synovial cells. Clin Exp Immunol 88(3): 448-54
12. Evereklioglu C (2005) Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol 50(4): 297-350
13. George RK, Chan CC, Whitcup SM, Nussenblatt RB (1997) Ocular immunopathology of Behcet's disease. Surv Ophthalmol 42(2): 157-62
14. Guillaume-Czitrom S, Berger C, Pajot C, Bodaghi B, Wechsler B, Kone-Paut I (2007) Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease. Rheumatology (Oxford) 46(10): 1570-3
15. Hamuryudan V, Moral F, Yurdakul S et al (1994) Systemic interferon alpha 2b treatment in Behcet's syndrome. J Rheumatol 21(6): 1098-100
16. Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H (2002) Interferon alfa combined with azathioprine for the uveitis of Behcet's disease: an open study. Isr Med Assoc J 4(11 Suppl): 928-30
17. Hauschild A, Kahler KC, Schafer M, Fluck M (2008) Interdisciplinary management recommendations for toxicity associated with interferon-alfa therapy. J Dtsch Dermatol Ges [epub ahead of print 26 March]
18. Imrie FR, Dick AD (2007) Biologics in the treatment of uveitis. Curr Opin Ophthalmol 18(6): 481-6
19. Kaser A, Novick D, Rubinstein M et al (2002) Interferon-alpha induces interleukin-18 binding protein in chronic hepatitis C patients. Clin Exp Immunol 129(2): 332-8
20. Kotter I, Vonthein R, Zierhut M et al (2004) Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Semin Arthritis Rheum 33(5): 311-19
21. Mackensen F, Max R, Becker MD (2006) Interferon therapy for ocular disease. Curr Opin Ophthalmol 17(6): 567-73
22. Meyers JA, Mangini AJ, Nagai T, Roff CF, Sehy D, van Seventer GA, van Seventer JM (2006) Blockade of TLR9 agonist-induced type I interferons promotes inflammatory cytokine IFN-gamma and IL-17 secretion by activated human PBMC. Cytokine 35(5-6): 235-46
23. Pfeffer LM, Dinarello CA, Herberman RB et al (1998) Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58(12): 2489-99
24. Piazzolla G, Giannelli G, Antonelli G, Tortorella C, Jirillo E, Schiraldi O, Antonaci S (1996) Effects of interferon-alpha treatment on neutrophil oxidative metabolism, lymphocyte proliferation and monocyte HLA class I antigen expression in patients with chronic hepatitis C. Immunopharmacol Immunotoxicol 18(4): 529-48
25. Pipitone N, Olivieri I, Cantini F, Triolo G, Salvarani C (2006) New approaches in the treatment of Adamantiades-Behcet's disease. Curr Opin Rheumatol 18(1): 3-9
26. Reddy KR (2004) Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). Semin Liver Dis 24: 33-8
27. Tilg H, Mier JW, Vogel W et al (1993) Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol 150(10): 4687-92
28. Treusch M, Vonthein R, Baur M et al (2004) Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease. Rheumatology (Oxford) 43(10): 1275-82
29. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M (2006a) Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 244(12): 1692-5
30. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Kir N, Urgancioglu M (2006b) Neovascularization of the optic disc in Behcet's disease. Jpn J Ophthalmol 50(3): 256-65
31. Wills RJ (1990) Clinical pharmacokinetics of interferons. Clin Pharmacokinet 19(5): 390-9